ClinicalTrials.Veeva

Menu

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (ELARA)

Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

Status and phase

Enrolling
Phase 3

Conditions

Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema

Treatments

Drug: Aflibercept 8 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT06491914
VGFTe-HD-OD-2444

Details and patient eligibility

About

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications.

The aim of the study is to see how safe and effective aflibercept HD injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.

Enrollment

400 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria for Participants with nAMD:

  1. ≥50 years of age

  2. History of choroidal neovascularization (CNV) lesions secondary to nAMD in the eye study, requiring continued anti-VEGF treatment, as determined by the investigator.

    Key Inclusion Criteria for Participants with DME:

  3. ≥18 years of age

  4. History of DME with central involvement (in the central subfield on Spectral domain optical coherence tomography [SD-OCT]) in the study eye, requiring continued anti-VEGF treatment, as determined by the investigator

    Key Inclusion for All Participants:

  5. Previously treated with ≥3 anti-VEGF IVT injections in the study eye in the 5 months (~150 days) prior to visit 1

Key Exclusion Criteria for Participants with nAMD:

  1. Evidence of CNV due to any cause other than nAMD in either eye

    Key Exclusion Criteria for Participants with DME:

  2. Evidence of macular edema due to any other cause other than diabetes mellitus in the study eye

  3. Active proliferative diabetic retinopathy (DR) in the study eye

NOTE: Other protocol defined inclusion / exclusion criteria apply.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

400 participants in 1 patient group

Aflibercept 8 mg
Experimental group
Description:
Participants previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications
Treatment:
Drug: Aflibercept 8 mg

Trial contacts and locations

25

Loading...

Central trial contact

Clinical Trials Administrator

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems